Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Maturitas(7)
Área temáticas
Ginecología, obstetricia, pediatría, geriatría(4)
Farmacología y terapéutica(2)
Medicina y salud(2)
Salud y seguridad personal(2)
Fisiología humana(1)
Origen
scopus(7)
Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.
OtherAbstract:Palabras claves:Autores:Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.Fuentes:scopusCalcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide
ArticleAbstract: Introduction Postmenopausal osteoporosis is a highly prevalent disease. Prevention through lifestylePalabras claves:calcium, diet, Excess-calcium risk, Postmenopausal osteoporosis, preventionAutores:Cano A., Goulis D.G., Lambrinoudaki I., Lopes P., Mishra G.D., Mueck A., Peter A. Chedraui, Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Tuomikoski P.Fuentes:scopusDrug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
ReviewAbstract: Background Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal ostPalabras claves:Alendronate, Bisphosphonates, Denosumab, Drug holiday, Risedronate, Zoledronic acidAutores:Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.Fuentes:scopusOsteoporosis management in patients with breast cancer: EMAS position statement
ReviewAbstract: Aromatase inhibitors (AIs) are the first-line recommended standard of care for postmenopausal estrogPalabras claves:adjuvant therapy, Aromatase inhibitors, Bisphosphonates, Breast Cancer, Denosumab, fractures, OSTEOPOROSIS, screeningAutores:Ceausu I., Depypere H., Faustino R. Pérez-López, Lambrinoudaki I., Mueck A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A., van der Schouw Y.T.Fuentes:scopusManagement of depressive symptoms in peri- and postmenopausal women: EMAS position statement
ArticleAbstract: Introduction: Globally, the total number of people with depression exceeds 300 million, and the inciPalabras claves:Depression, Early menopause, EMAS, menopausal hormone therapy, Menopausal transition, Model of care, PERIMENOPAUSEAutores:Bitzer J., Cano A., Ceausu I., Durmusoglu F., Erkkola R., Goulis D.G., Karageorgiou V., Kiesel L., Lambrinoudaki I., Lindén Hirschberg A., Lopes P., Peter A. Chedraui, Pines A., Rees M., Spyropoulou A., Stute P., van Trotsenburg M., Zervas I.Fuentes:scopusInterventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement
ReviewAbstract: Background Ovarian cancer is a leading cause of female gynecological cancer-related death, and therePalabras claves:bilateral oophorectomy, Bilateral salpingectomy, BRCA gene mutation, Combined oral contraceptives, Fallopian tubes cancer, hysterectomy, Non-steroid anti-inflammatory drugs, obesity, Ovarian borderline tumors, Ovarian Cancer, smokingAutores:Ceausu I., Depypere H., Faustino R. Pérez-López, Kehoe S., Lambrinoudaki I., Mueck A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P.Fuentes:scopusMenopause and diabetes: EMAS clinical guide
ArticleAbstract: Introduction: Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independentlyPalabras claves:menopausal hormone therapy, MENOPAUSE, Type 2 Diabetes mellitusAutores:Anagnostis P., Cano A., Goulis D.G., Jaremek J.D., Lambrinoudaki I., Lopes P., Meczekalski B., Mishra G.D., Mueck A., Paschou S.A., Peter A. Chedraui, Rees M., Rogowicz-Frontczak A., Senturk L.M., Simoncini T., Slopien R., Stevenson J.C., Stute P., Tuomikoski P., Wender-Ozegowska E., Zozulinska-Ziolkiewicz D.Fuentes:scopus